Thermo Fisher Scientific, already a big player in providing services to the biopharmaceutical industry, is adding to its technology capabilities with the $9 billion acquisition of clinical trial ...

Thermo Fisher Scientific is breaking out the big bills to score a clinical research treat. With $8.875 billion in cash, the life science giant is adding Clario Holdings to its goodie bag, the company ...

Thermo Fisher Scientific TMO1.74%increase; green up pointing triangle agreed to acquire endpoint data solutions provider Clario Holdings from a shareholder group for $8.88 billion in cash. The ...

Thermo Fisher has also agreed to pay up to $400 million of earn-out payments based on the performance of the business in 2026 and 2027 The transaction is expected to be completed by the middle of 2026 ...

From smartphones to autonomous cars to AI supercomputers, nearly every electronic innovation we use today depends on complicated structures at the atomic scale within silicon chips. As these chips ...

Thermo Fisher Scientific’s plan for growth is paying off as the biopharma service provider and supplier posted a sales bump in the third quarter. The company, which has business lines ranging from ...

Investing.com -- Thermo Fisher Scientific Inc. (NYSE:TMO) reported third-quarter results that exceeded analyst expectations, with adjusted earnings per share and revenue both surpassing consensus ...

Thermo Fisher Scientific recently announced a collaboration with OpenAI to integrate advanced artificial intelligence into its Accelerator Drug Development solution, aiming to enhance the speed and ...

The collaboration will help to improve the speed and success of drug development, the company said. As part of the collaboration, Thermo Fisher is embedding OpenAI APIs (Application Programming ...

WALTHAM, Mass., October 16, 2025--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced plans to further increase the impact of Thermo Fisher’s ...

Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the stocks Jim Cramer put under the microscope. When Cramer was asked about the stock, he commented: “Oh yeah… they really got hurt by COVID. I gotta ...